$523.39 Million in Sales Expected for Allscripts Healthcare Solutions Inc (MDRX) This Quarter

Equities analysts predict that Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) will post sales of $523.39 million for the current quarter, according to Zacks. Ten analysts have issued estimates for Allscripts Healthcare Solutions’ earnings, with the highest sales estimate coming in at $526.90 million and the lowest estimate coming in at $520.48 million. Allscripts Healthcare Solutions posted sales of $429.40 million during the same quarter last year, which would indicate a positive year over year growth rate of 21.9%. The business is scheduled to report its next quarterly earnings results after the market closes on Thursday, February 15th.

On average, analysts expect that Allscripts Healthcare Solutions will report full year sales of $523.39 million for the current financial year, with estimates ranging from $1.81 billion to $1.82 billion. For the next fiscal year, analysts expect that the business will report sales of $2.14 billion per share, with estimates ranging from $2.11 billion to $2.17 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Allscripts Healthcare Solutions.

Several analysts have commented on the stock. Zacks Investment Research raised shares of Allscripts Healthcare Solutions from a “sell” rating to a “hold” rating in a research report on Thursday, January 25th. Robert W. Baird reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Allscripts Healthcare Solutions in a research report on Tuesday, October 17th. Citigroup assumed coverage on shares of Allscripts Healthcare Solutions in a research report on Thursday, January 4th. They issued a “buy” rating on the stock. SunTrust Banks lowered shares of Allscripts Healthcare Solutions from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. They noted that the move was a valuation call. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Allscripts Healthcare Solutions in a research report on Sunday, January 28th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the company. Allscripts Healthcare Solutions presently has a consensus rating of “Buy” and a consensus target price of $15.66.

Allscripts Healthcare Solutions (NASDAQ:MDRX) opened at $14.12 on Friday. The firm has a market cap of $2,462.68, a PE ratio of 31.70, a P/E/G ratio of 1.92 and a beta of 1.18. The company has a current ratio of 0.98, a quick ratio of 0.98 and a debt-to-equity ratio of 1.20. Allscripts Healthcare Solutions has a 12-month low of $11.25 and a 12-month high of $16.13.

In other news, President Richard J. Poulton sold 15,000 shares of Allscripts Healthcare Solutions stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $14.26, for a total value of $213,900.00. Following the completion of the transaction, the president now owns 1,351,773 shares in the company, valued at $19,276,282.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Brian Farley sold 5,000 shares of Allscripts Healthcare Solutions stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $14.35, for a total transaction of $71,750.00. Following the completion of the transaction, the executive vice president now owns 191,607 shares of the company’s stock, valued at approximately $2,749,560.45. The disclosure for this sale can be found here. Insiders sold 56,796 shares of company stock valued at $804,842 in the last quarter. Corporate insiders own 0.75% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. Shelton Capital Management purchased a new position in Allscripts Healthcare Solutions during the second quarter valued at approximately $170,000. Sheaff Brock Investment Advisors LLC purchased a new position in Allscripts Healthcare Solutions during the third quarter valued at approximately $174,000. Quantitative Systematic Strategies LLC purchased a new position in Allscripts Healthcare Solutions during the fourth quarter valued at approximately $182,000. Crossmark Global Holdings Inc. purchased a new position in Allscripts Healthcare Solutions during the third quarter valued at approximately $187,000. Finally, Oakbrook Investments LLC purchased a new position in Allscripts Healthcare Solutions during the fourth quarter valued at approximately $194,000.

COPYRIGHT VIOLATION WARNING: “$523.39 Million in Sales Expected for Allscripts Healthcare Solutions Inc (MDRX) This Quarter” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.americanbankingnews.com/2018/02/10/523-39-million-in-sales-expected-for-allscripts-healthcare-solutions-inc-mdrx-this-quarter-2.html.

Allscripts Healthcare Solutions Company Profile

Allscripts Healthcare Solutions, Inc (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions.

Get a free copy of the Zacks research report on Allscripts Healthcare Solutions (MDRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Allscripts Healthcare Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply